Amaryl

Glimepiride

Type 2 NIDDM.

Initially 1 mg daily. Usual dose range: 1-4 mg daily. Max daily dose: 6 mg (in exceptional cases, 8 mg).

Should be taken with food: Take immediately before the 1st main meal of the day. Do not skip meals. Swallow whole, do not chew.

Hypersensitivity to glimepiride, other sulfonylureas or sulfonamides. Type 1 IDDM (eg, w/ history of ketoacidosis); diabetic ketoacidosis; diabetic precoma or coma. Severe liver function impairment; dialysis patients. Not to be taken during pregnancy & lactation.

Adjust dose or entire therapy if risk factors of hypoglycemia are present eg, unwillingness or (more commonly in older patients) incapacity of patient to cooperate; undernutrition, irregular mealtimes, or skipped meals; imbalance between physical exertion & carbohydrate intake; diet alterations; alcohol consumption, especially in combination w/ skipped meals; impaired renal function; severe impairment of liver function; overdosage; certain uncompensated disorders of endocrine system affecting carbohydrate metabolism or counterregulation of hypoglycaemia (eg, in certain disorders of thyroid function & anterior pituitary or adrenocortical insufficiency); concurrent administration of certain other medicines. Milder or absent symptoms of hypoglycemia eg, in patients w/ autonomic neuropathy or receiving concurrent treatment w/ β-blockers, clonidine, reserpine, guanethidine or other sympatholytic drugs. Exceptional stress situations eg, trauma, surgery, infections w/ fever. Patients w/ G6PD deficiency. Regulary check glucose levels in blood & urine; proportion of glycated Hb. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Administer treatment at least 4 hr prior to colesevelam. May affect ability to drive & use machinery. Elderly.

Hypoglycemia; adrenergic counterregulation; temporary visual impairment; GI symptoms. Rarely, thrombocytopenia, haemolytic anaemia (eg, erythrocytopenia), granulocytopenia, agranulocytosis & pancytopenia. Severe hypoglycaemia, certain changes in blood picture, severe allergic or pseudoallergic reactions, or liver failure.

Potentiated blood sugar-lowering effect w/ insulin & other, oral antidiabetics (metformin), ACE inhibitors, allopurinol, anabolic steroids & male sex hormones, chloramphenicol, clarithromycin, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, fluconazole, guanethidine, ifosfamide, MAOIs, miconazole, p-aminosalicylic acid, pentoxifylline (high dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, certain long acting sulfonamides, tetracyclines, tritoqualine, trofosfamide. Weakened blood sugar-lowering effect w/ acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine (adrenaline) & other sympathomimetic agents, glucagons, laxatives (after protracted use), nicotinic acid (in high doses), oestrogens & progestogens, phenothiazines, phenytoin, rifampicin, thyroid hormones. Either potentiated or weakened blood sugar-lowering effect w/ H₂ receptor antagonists, β-blockers, clonidine & reserpine; in both acute & chronic alcohol intake. Decreased glucose tolerance & increased hypoglycemia tendency w/ β-blockers. Reduced or absence of adrenergic counterregulation signs w/ β-blockers, clonidine, guanethidine & reserpine. Potentiated or weakened effect of coumarin derivatives. Reduced absorption from GI tract w/ colesevelam.

Antidiabetic Agents

A10BB12 - glimepiride ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

D